ArticleFrontiers in public health2026
The prevalence and medical costs of neovascular glaucoma in a tertiary medical center in China from 2016 to 2024.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neovascular glaucoma (NVG) is a severe, vision-threatening secondary glaucoma. With a higher incidence and earlier onset of its primary diseases, NVG may increase the healthcare burden. This study investigate the demographic characteristics and medical costs of NVG in a tertiary medical center in China. Methods: This retrospective cohort study included patients diagnosed with NVG, angle neovascularization, or rubeosis iridis at Peking University Third Hospital from January 2016 to December 2024. Data collected included demographics (gender, age, diagnosis, and etiology), treatment (conservative or surgical treatment), number of visits, and medical costs. Results: A total of 1,275 patients were included, with a mean age of 59.9 ± 16.3 years (range 2-98). 64.5% of patients were aged 45 - 75 years. Male patients predominated (828 vs. 447, ratio 1.9:1) and had an earlier age of onset than females (56.6 ± 16.1 years vs. 62.3 ± 14.8 years; Discussion: NVG requires increased attention to the risk of DR in middle-aged and older men. Developing age-specific strategies for allocating outpatient and surgical resources is essential to reduce the economic burden of NVG across different age groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.